Overview

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2019-12-23
Target enrollment:
Participant gender:
Summary
This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.
Phase:
Phase 3
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Bevacizumab
Erlotinib Hydrochloride